Should We Preclude Phase 1 Clinical Trials From Enrolling Elderly Individuals?

No abstract is available for this paper.

• Publication year

  2015

• Venue

  Cancer Control: Journal of the Moffitt Cancer Cente

• Publication date

  2015-04-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1177/107327481502200216PMID 26068770
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Perceptions by the oldest old of successful aging, Vitality 90+ Study.

  2015cited by this paper
• Biology of cancer and aging: a complex association with cellular senescence.

  2014cited by this paper
• Targeted therapy in older patients with solid tumors.

  2014cited by this paper
• The Role of Age on Dose-Limiting Toxicities in Phase I Dose-Escalation Trials

  2014cited by this paper
• Participation of the elderly population in clinical trials: barriers and solutions.

  2014cited by this paper
• Potential drug interactions and chemotoxicity in older patients with cancer receiving chemotherapy.

  2014cited by this paper
• Simple biologically informed inflammatory index of two serum cytokines predicts 10 year all-cause mortality in older adults.

  2014cited by this paper
• Studying cancer treatment in the elderly patient population.

  2014cited by this paper
• Polypharmacy and the management of the older cancer patient.

  2013cited by this paper
• Association of leukocyte telomere length with breast cancer risk: nested case-control findings from the Shanghai Women's Health Study.

  2013cited by this paper
• Predicting the risk of chemotherapy toxicity in older patients: The Chemotherapy Risk Assessment Scale for High‐Age Patients (CRASH) score

  2012cited by this paper
• Predicting chemotherapy toxicity in older adults with cancer: a prospective multicenter study.

  2011cited by this paper
• Participation and survival of geriatric patients in Phase I clinical trials: the Karmanos Cancer Institute (KCI) experience.

  2011cited by this paper
• Phase I Clinical Trials in Patients ≥80.

  2011cited by this paper
• Safety and tolerability of phase I/II clinical trials among older and younger patients with acute myelogenous leukemia

  2011cited by this paper
• Breast cancer genomes--form and function.

  2010cited by this paper
• Adverse events in volunteers participating in phase I clinical trials: a single-center five-year survey in 1,559 subjects.

  2005cited by this paper
• Enrollment of elderly patients in clinical trials for cancer drug registration: a 7-year experience by the US Food and Drug Administration.

  2004cited by this paper
• Relation between age and clearance rate of nine investigational anticancer drugs from phase I pharmacokinetic data

  2004cited by this paper
• Multiple primary malignancies.

  2004cited by this paper
• Multiple primary malignancies.

  1966cited by this paper

• No citing papers are available for this paper.